HeraMED Ltd (ASX: HMD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
HeraMED Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
HeraMED Ltd (ASX: HMD)
Latest News
Healthcare Shares
HeraMED (ASX:HMD) share price tanks despite US healthcare deal
HMD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About HeraMED Ltd
HeraMED Ltd is engaged in developing, connected pregnancy monitoring solutions for home and professional use. It has developed a foetal heartbeat monitor called HeraBEAT which is a medical-grade, clinically-validated, smart and connected Ultrasound Foetal Doppler device predominantly for use by an expectant mother to self-monitor her foetus' heart rate (FHR). It is also focused on the commercialization and deployment of its HeraCARE pregnancy monitoring solution. Geographically, the company generates a majority of its revenue from the United States of America followed by Australia and Israel.
HMD Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
02 Apr 2024 | $0.02 | $0.00 | 0.00% | 396,047 | $0.02 | $0.02 | $0.02 |
27 Mar 2024 | $0.02 | $0.00 | 0.00% | 13,212 | $0.02 | $0.02 | $0.02 |
26 Mar 2024 | $0.02 | $0.00 | 0.00% | 17,500 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
28 Mar 2024 | David Hinton | Issued | 71,667 | $1,433 |
Rights issue.
|
09 Oct 2023 | Ronald (Ron) Weinberger | Issued | 7,500,000 | $465,000 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr David Hinton | Non-Executive Director | Aug 2018 |
Mr Hinton has an career in the information and technology sectors and is currently Chief Financial Officer and Company Secretary of Empired Limited, an ASX listed IT and software services provider and prior to that Amcom Telecommunications Ltd. Mr Hinton is also a Director of Auspire - The Australia Day Council of Western Australia.
|
Dr Ronald (Ron) Peter Weinberger | Executive Director | Nov 2023 |
Dr Weinberger is an experienced technology and business development executive, with a demonstrated history of building significant value at multiple levels in the medical device industry. During his time at Nanosonics, he co-developed their platform technology, launched their breakthrough product Trophon globally and created North American sales team to work alongside GE Healthcare. He also developed the distribution strategy for Europe having partnered with Toshiba Medical Systems (now Canon Medical Systems) and Miele Professional.
|
Mr Timothy (Tim) Chapman | Non-Executive Director | Mar 2024 |
Mr Chapman has over 20 years experience in financial services, having advised on a myriad of corporate transactions and capital raisings for public and private companies through IPOs, private placements, reverse takeovers as well as many mergers and acquisitions. Tim has spent the last 15 years of his career advising micro and small companies across a range of industries including healthcare and health tech. Specifically Tim has been supporting HeraMED in an advisory capacity as it has transitioned from a R&D hardware business into a software SaaS business addressing the range of challenges within maternity care.
|
Mr Cameron Jones | Chief Financial OfficerCompany Secretary | Apr 2024 |
-
|
Sivan Sadan | Chief Financial Officer |
-
|
|
Cameron Jones | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Citicorp Nominees Pty Limited | 12,187,408 | 5.02% |
Altshuler Shaham Trusts Ltd <Holley Pharma Co Ltd A/C> | 10,857,385 | 4.47% |
Altor Capital Management Pty Ltd <Altor Alpha Fund A/C> | 10,628,875 | 4.38% |
Freeman Road Pty Ltd <The Avenue A/C> | 10,543,779 | 4.35% |
Altshuler Shaham Trusts Ltd <David Groberman A/C> | 9,709,170 | 4.00% |
Altshuler Shaham Trusts Ltd <Tal Slonim A/C> | 9,709,170 | 4.00% |
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED | 8,294,621 | 3.42% |
S & S Browne Assets Pty Ltd <S & S Browne Investment A/C> | 4,096,616 | 1.69% |
Ratdog Pty Ltd | 3,670,000 | 1.51% |
Bryntirion Capital | 3,637,273 | 1.50% |
Ripperday Pty Ltd | 3,457,496 | 1.42% |
Chris Ntoumenopoulos | 3,025,000 | 1.25% |
Tamorer Pty Ltd <Wylie Family A/C> | 2,909,091 | 1.20% |
Mayo Clinic | 2,767,691 | 1.14% |
Mr Alan Jonathan Berrick | 2,552,273 | 1.05% |
Dr Matthew Farrugia | 2,354,014 | 0.97% |
Netwealth Investments Limited <Wrap Services A/C> | 2,171,276 | 0.89% |
Cardup Syndicate Holdings Pty Ltd <The Cardup Syndicate A/C> | 2,050,000 | 0.84% |
Mr John Vieira & Mrs Tracey Lois Vieira <Bayview Retirement Plan A/C> | 1,656,000 | 0.68% |
Dr Stuart Lloyd Phillips & Mrs Fiona Jane Phillips <Sl & Fj Phillips Pension A/C> | 1,585,000 | 0.65% |
North of the River Investments Pty Ltd | 1,508,042 | 0.62% |